Mosaic ImmunoEngineering (CPMV) Restructuring Costs (2023)
Mosaic ImmunoEngineering (CPMV) posted quarterly Restructuring Costs of $6000.0 for Q3 2023, up 2900.0% quarter-over-quarter from $200.0 in Q1 2023.
Mosaic ImmunoEngineering (CPMV) Restructuring Costs (2023) Analysis & Trends
Mosaic ImmunoEngineering's Restructuring Costs history runs 1 years deep, the most recent figure standing at $6000.0 for Q3 2023.
- In Q3 2023, Restructuring Costs changed N/A year-over-year to $6000.0; the TTM figure through Jun 2024 stood at $6000.0 (changed N/A YoY), while the FY2023 annual figure was $6200.0, changed N/A from the prior year.
- Restructuring Costs for Q3 2023 stood at $6000.0, up from $200.0 in the prior quarter.
- The five-year high for Restructuring Costs was $6000.0 in Q3 2023, with the low at $200.0 in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Mosaic ImmunoEngineering | 527,536.97 | 527,536.97 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | 6,000.00 |
| Mar 31, 2023 | 200.00 |